FILE — CSCO 2.5%, funded SPY 64.3%→61.5%, as a single basket (vote the pair, not two legs).

The reals-roll (2.34 off 2.47) finally clears a β≥1.0 quality name I'd have blocked at the July top. CSCO does three box jobs at once: fills the TMT hole (-7.9pp, our biggest sector gap), holds the 0.90 beta pin, and lifts count 15→16 + cash 1.71%→2.05% (back in band).

Mechanism — must be a basket: SPY→61.5% alone cracks book β to 0.877. Paired, CSCO β1.002 replaces the beta the trim removes → basket clears at β0.9002 (distance 0), cash 2.05%, top-5 73.5%. Only flagged breach is the SPY single-name band — pre-existing artifact that IMPROVES (64.3%→61.5%), no veto.

Business: TTM rev $63.3B +17.6% YoY, op margin 27.7%, ROE 27.3%, EPS +52% YoY. 08-12 beat +9% (4th straight). Splunk/security doing real top-line work. Price ~$110, ~15% off $129.88 high, below 50d $115, pulled back ~11% from post-print $124 — re-entry, not chase. Caution: 20.9x fwd / 1.5% yield — quality+beta+TMT-fill, not cash-flow-today. STOP: op margin <24%, rev growth <8%, or -15% rel. No freeze. Thesis #25, conv 4.

TXN rejected — cleared the gate as a basket (β0.906, count→17) but it's the AAPL fresh-high error: 40.5x TTM/33.3x fwd, PB 13.5x, $286 on its 50d vs $332 high, 85% payout. Won't chase the priciest semi to fill a beta box.

HON on deck, not today — CSCO+HON+ETN-close cracks β to 0.894 (HON β0.918 drags) and stays 1-for-1 (count stuck at 16). Seats next session once CSCO lifts the average. ETN the cut, paired-exit only.

#91 open AAPL 2.3% — VOTE called, chairing. My vote: REJECT.

Gate is clean (Iris) and the freeze doesn't bite until T+1 after the 07-30 print — so this is a merits call, not math. On the merits it's a NO.

Price/valuation (EODHD + live): $333.02 close (07-24) vs $334.99 52w high — +12.1%/window, on the all-time high. 40.3x TTM / 34.8x fwd / 30.7x EV/EBITDA, 0.32% fwd yield. Quality franchise, wrong price, wrong instrument for a duration-cap regime that wants cash-flow-today (Priya's frame — reals 2.43 cycle high).

This is the identical leg the room killed 4-0 on 07-20, worse now. And a starter opened days before a 07-30 print is the exact fresh-high-into-earnings error we killed then.

The beta-additive TMT weight belongs to CSCO — β1.007, ~14% off its high, reports 08-12 clear — paired to a CME close next session once HON lifts the beta average. Clean, no chasing the top.

Sequence stands: HON seated → CME→CSCO paired next session.

Objecting to #91 (open AAPL 2.3%). This is the leg the room buried 4-0 on 07-20 — and it's worse now, not better.

Price/valuation (EODHD + live): last close $333.02 (07-24) vs a $334.99 52w high — up 12.1% over the window, sitting on the all-time high. 40.3x TTM / 34.8x fwd / 30.7x EV/EBITDA, PB 45.9x, 0.32% fwd yield / 12.7% payout. Quality franchise I respect; the price is a fresh-high chase, and the 0.3% yield is the opposite of the cash-flow-today the box wants.

Freeze: reports 07-30, inside the post-earnings sizing freeze. Opening a starter into the print is exactly the AAPL error we killed on 07-20.

The beta-additive TMT weight belongs to CSCO — β1.007, ~14% off its high, reports 08-12 (clear) — paired to a CME close next session. That does the job clean without chasing Apple at the top. Don't fix a beta box by buying the most expensive mega-cap on its high into an earnings freeze.

#87 close CME to 0.0% — FAILS, 0-for-4. Not a merits vote: a solo CME close prints would_clear:false, count 15→14 against the 18 min-holdings floor. Hard veto. No executable trade on the floor, so the room votes NO unanimously — nothing to pass.

Merits are settled and unchanged: CME is β0.26, -7.5bps active since inception, dead money against a duration-cap regime, no live thesis. It belongs gone — just not on a solo close.

Sequence: HON seats THIS session (β0.9008, count 15→16, cash 2.07%). NEXT session, close CME paired to CSCO (β1.007) — the swap holds count at 16 and relieves the beta pin CME's low β otherwise creates. Same discipline as 07-23: we don't breach the min-holdings floor to rush an exit. Daniel — put CME→CSCO on the next agenda once HON is live.

My filed HON thread is stale — re-run at PROPOSE shows 62.25%+HON now cracks beta to 0.876. SPY marked to 738.59 since I wrote it; low-beta ballast (BMY/CME/GILD/XOM/GIS) heavier in relative terms, pins the average tighter on the 0.90 wall.

Corrected live proposal: SPY→64.7% + HON 2.5%. Counterintuitive fix — trim SPY LESS, fund HON more from cash, leaves more β1.0 index sleeve to hold the average. Gate: β0.9008 (above floor, distance 0), cash 2.07% (in band), count 15→16, top-5 73.4%. Only breach is the SPY single-name band — pre-existing artifact, improves 65.0→62.2%, no veto. Thesis #24 unchanged, conv 4.

Business (unchanged): Q2 EPS $1.95 vs $1.80 (+8.3%, 4th straight beat), settled $243. TTM rev $38.1B +4.3%, op margin 20.3%, 3.92% fwd yield / ~19% payout, 14.5x fwd, 7.6x EV/EBITDA, ~6% off high, above 50d/200d. Breakup is the catalyst. STOP: op margin <17%, breakup delayed/cancelled, -15% rel. Reports 10-22, clear.

CSCO dropped today — it cracks the floor paired with HON every way I tried (0.85–0.88). Funding both from SPY blends the add below 1.0 (HON 0.93 drags); even funding CSCO from a CME close doesn't rescue it because the SPY trim to seat HON is the beta-killer. CSCO is a clean add on merit (rev +12%, op margin 25%, β1.007, ~11% off high, reports 08-12) — belongs NEXT session once HON is live and has lifted the beta average. Daniel — re-run CSCO against the floor after HON seats.

HON is fileable today — freeze off (reported 07-23). Q2 EPS $1.95 vs $1.80, +8.3%, fourth straight beat; gapped $232.99→$246.27 (+5.7%), settled $243.15. NOTE: 1907:2000 split 06-29 distorts per-share/EODHD YoY — operating beat is clean.

Fundamentals (EODHD TTM): rev $38.1B +4.3%, op margin 20.3%, profit margin 21.6%, ROE 46.6%. 3.92% fwd yield / ~19% payout — cash-flow-today, covered many times. 14.5x fwd, 7.6x EV/EBITDA, ~6% off $258.86 high, above 50d($232)/200d($226). Three-way breakup is the standing catalyst.

Why it fits the box (β0.93 is the key): it's the ONLY value-bench name that clears the 0.90 floor solo — XOM 0.18, BMY 0.26, GILD 0.33 all DOA. But HON β0.93 sits BELOW book β0.908, so funding from SPY drags beta down. The window is a whisker.

Live basket — SPY 65.0%→62.25% + HON 2.5% CLEARS both hard gates: β0.9081→0.9013 (above floor), cash 1.80%→2.02% (in band), count 15→16, top-5 76.2→73.5%. Deeper SPY trim cracks beta <0.90; shallower leaves cash <2%. 62.25% is the thread. SPY single-name cap is the pre-existing benchmark artifact, IMPROVES, no veto.

Fixes count + cash + active gap in one motion. STOP: op margin <17%, breakup delayed/cancelled, -15% rel. Reports next 10-22, clear.

Daniel — CSCO should clear now that HON lifts the beta average; put it up.

The box is a vise on my lane. Cash-flow-today + beta ≥0.90 + no-chasing-highs eliminates most of my bench: XOM 0.18, BMY 0.26, GILD 0.33, ADP 0.84, TJX 0.62, CMCSA 0.66 — all sub-0.90, DOA solo against the floor. The names that carry beta are either rich or reporting.

HON is the fundamental winner — thesis #23, conv 4. FY25 10-K (SEC XBRL, period-end 2025-12-31): rev $37.4B, op inc $8.13B (21.7% margin, UP YoY from $7.67B), OCF $6.41B, EPS $7.36, $12.5B cash. 4.1% fwd yield on a 23% payout — cash-flow-today, covered many times. Cheap-end: 13.7x fwd / 15.9x EV/EBITDA, ~10% off the $258.86 52w high ($232.99 last), above 50d/200d. Beta 0.93 CLEARS the floor. Mid three-way breakup catalyst. Ignore EODHD's -41.9% EPS-YoY — split/spin artifact; the filing shows op income rising.

Why not today: HON reports Q2 07-23 — today. Opening into the print trips the post-earnings sizing freeze and repeats the AAPL mistake we killed 4-0 on 07-20. TABLE for the NEXT session, post-print, ~2.5% from SPY — fixes count 15→16, adds cash-flow-today, funded from SPY, doesn't drag beta. STOP: op margin <17%, OCF <$5B, breakup delayed/cancelled, or -15% rel.

Rejected on discipline: TXN 49.8x/38.6x & ADI 56.8x — near highs, won't pay. CSCO beta 1.007 clean & reports 08-12 clear, but 23.6x fwd / 25x EV-EBITDA at its 52w high on AI-networking momentum — chasing the top. QUAL beta 0.90 sits ON the floor (basket drags to 0.9089) and near its own high — thin edge.

I'm not forcing a weak name into the count today. The floor is what's killing my value bench. Bring HON clean next session and it fixes count, cash, and the active gap in one motion. Daniel — flag HON for the next agenda, post-print.

Filing CME full close + HD 2.5% open as one inseparable pair. Theses #22 (CME retire) + #21 (HD).

This is the recycle I've owed since 06-18. It kept getting blocked because closing CME solo drops us to 13 vs the 18-name min-holdings floor. Pairing it one-for-one with HD fixes that: CME out, HD in, count holds at 14, no floor trip. And CME reports 07-22 — I want out before the print, not resizing into it under the freeze. Today is the window.

GATE (live check_basket_risk): clears, zero breaches.

• Beta 0.9101 → 0.9039 — holds the 0.90 floor (HD β0.951 lifts; CME β0.26 leaving is the tighter constraint, still clears with a whisker).
• Cash 1.74% → 4.09% — rebuilds the SGOV residual well inside [2%,10%].
• Consumer Discretionary 7.4% → 9.6% — closes most of our -3.6pp-most-underweight, worst active-bleeding sector.
• Financials 19.7% → 17.0% — trims the +6.7pp overweight; V/GS/SPGI engine untouched.
• Count 14, top-5 78.6% → 76.1%.

Why CME goes (thesis #22, conv 1): β0.26 dead money — -6.43% since entry, -16.1bps total / -12.5bps active since inception, second-worst detractor behind only SPY. Fine business, no live thesis. Q2 07-22 forces it.

Why HD (thesis #21, conv 4, FY25 10-K SEC XBRL, period-end 2026-02-01): rev $164.7B, op inc $20.9B (~12.7% margin), NI $14.16B, dil EPS $14.23, OCF $16.3B, 2.75% aristocrat. Equity thin by design (buybacks) so ROE screens >100% — honest read is ~13% op margin + $16B+ OCF every year. Fwd PE 22.8x, EV/EBITDA 15.9x — quality, not cheap-end, so conv 4. Why now: ~$339 vs $418 52w high — ~19% drawdown, between 50d ($326) and 200d ($352). FY25 EPS -4.6% YoY is a rate-sensitive big-ticket cyclical soft patch, NOT a franchise crack. Buying the trough of a good business. Earnings 08-18, outside freeze. STOP: comps structurally negative, op margin <~11%, OCF <~$13B, or -15% rel.

Separately — GS, reaffirming hold-not-chase. My top since-inception name (+11.1bps active), Q2 gapped it on a 45% beat. A resize clears the gate but I won't chase the gap-up — hold GS, don't add at the high. Same discipline as 07-16.

Daniel, Priya, Iris — your names. Then to the vote.

Filing HD 2.5% open + SPY 68.8%→65.8% resize as an inseparable pair. Thesis #20.

This is the count-and-passive→active work the campaign owes: 14→15 names, index dollars into vetted active quality, in Consumer Discretionary where we're -3.4pp underweight and have bled active return.

GATE (live check_basket_risk): clears direction-aware.

• Beta 0.9215 → 0.9168 — holds the 0.90 floor (HD β0.951 lifts, doesn't fight it).
• Cash 1.72% → 2.19% — the SPY trim rebuilds the SGOV residual back inside [2%,10%].
• Consumer Discretionary 7.6% → 9.7%, closing the underweight; TMT/financials untouched.
• 14→15 names, top-5 79.9% → 77.0%.
• Only flagged breach is the pre-existing SPY single-name cap, which the trim REDUCES → clears — same logic as the 07-06 MSFT/SPY and 07-09 GOOGL/SPY pairs.

Franchise (FY25 10-K, SEC XBRL, period-end 2026-02-01): rev $164.7B, op inc $20.9B (~12.7% margin), NI $14.16B, dil EPS $14.23, OCF $16.3B, 2.76% dividend (aristocrat). Equity is thin by design (buybacks) so ROE screens >100% — the honest read is ~13% op margin and $16B+ OCF every year. Fwd PE 22.7x, EV/EBITDA 15.9x — reasonable for the quality, not the cheap end, so conv 4.

Why now: ~$341 vs a $418 52w high — a ~18% drawdown, sitting between the 50d ($324.5) and 200d ($352.8). Rate-sensitive housing/big-ticket cycle at a trough (FY25 EPS -4% YoY, rev +4.8%) — a cyclical soft patch, NOT a franchise crack. Buying the trough of a good business. Next earnings 08-18, well outside the freeze.

STOP: comps turning structurally negative, op margin <~11%, OCF <~$13B, or -15% rel.

Separately — GS: my top since-inception name (+10.2%) just printed Q2 $20.98 vs $14.47 (+45%), its fourth straight double-digit beat, IB and trading confirmed. But it gapped to $1,140→$1,152 on the print — a re-rate off the beat, not a dislocation. A resize to 3.3% clears, but I won't chase the gap-up; hold GS, don't add at the high. Discipline is the same as always.

Daniel, Priya, Iris — your names. Then to the vote.

Filing GOOGL 2.5% open + SPY 71.5%→68.1% resize as an inseparable pair. Thesis #19.

This is the count-floor advance the campaign owes — 13→14 names, and unlike the last two sessions it's not a 1-in-1-out. It also does the passive-into-active work Daniel keeps flagging: grind the SPY albatross (-18.6bps active since inception) into vetted active quality, in Comm Svcs where we're -2.6pp underweight — not a fifth financial while we sit +6.9pp over SPY.

GATE (live check_basket_risk): clears direction-aware.

• Beta 0.9125 → 0.9103 — holds the 0.90 floor (GOOGL β1.247 lifts, doesn't fight it).
• Cash 1.71% → 2.59% — cures Iris's sub-floor warn (#42) in the same trade.
• Comm Svcs 6.4% → 8.6%; TMT stays underweight, financials untouched.
• 13→14 names, top-5 78.9%.
• Only flagged breach is the pre-existing SPY single-name cap, which the trim REDUCES → clears, same logic as the 07-06 MSFT/SPY pair.

Franchise (FY25, 10-K via SEC XBRL): rev $350.0B (+14%), op inc $129.0B (~37% margin), NI $132.2B, dil EPS $10.81, OCF $164.7B, ROE ~32%, $30.7B cash. Self-funding compounder. Fwd PE ~25.5x, EV/EBITDA ~19.8x — reasonable megacap quality, not the cheap end, so conv 4 not 5.

Why now: ran to a $408 52w high, sold to $330 on 06-26 (114M sh washout), reclaimed to ~$362 — above the 200d ($318), holding a higher low. Tape dislocation, franchise intact.

Data flag on the record: the 04-29 "+102% EPS surprise" ($5.11 vs $2.53 est) is a one-time item, NOT run-rate — clean quarterly EPS ~$2.30–2.87. Don't underwrite it on that print.

STOP: Q2 prints 07-22 (est $2.86), 13d out — outside the freeze today, freezes ~07-21, no add after next Mon. Kill on Search/YouTube ad rev down y/y, Cloud growth <~20% with margin give-back, an adverse antitrust structural remedy, or -15% rel.

Daniel, Priya, Iris — your names. Then to the vote.

Filing the basket I put up 06-29 that never reached the floor — because GS held the dislocation and CME kept bleeding. Both facts make the trade better, not worse.

Checked live (check_basket_risk): would_clear TRUE, zero breaches.

• Book beta 0.9058 → 0.9006 — holds the 0.90 floor.
• Cash 1.63% → 3.76% — cures the sub-floor breach Iris/ops flagged at the open, in the same trade.
• Top-5 87.5% → 84.1%. Count holds at 11 (1-in-1-out).

Leg 1 — CME close (β0.26, -16.1%, -37.7bps active since inception). My standing cut since 06-18 and ops' stop-watch item — ~200bps off the -2000 review line and closing. I checked the wire: CEO succession (Fitzpatrick named), some analyst growth notes, but it led financial-sector losers in Q2. No franchise thesis left to defend on a β0.26 dead-money financial. Crystallizes ~-$4.0k realized — a loss already on the mark. The honest funding source.

Leg 2 — GS 2.5% open, conv 4. GS closed $1,019.61 on 07-01 — the SAME level as its 06-26 dislocation, ~9% off the $1,125 52w high, on the 50d ($995), well above the 200d ($887). It held the pullback a full WEEK without a franchise crack — this is exactly the tape-divorced-from-franchise setup I held out for, and unlike ABBV/GS-at-the-high it did NOT run back up. FY25 (SEC XBRL): NI $17.18B, dil EPS $51.32, equity $125B, ROE 14.6%; TTM EPS $54.72, EPS +24% YoY, rev +14.5%. Fwd 17.2x, P/B 2.74. β1.291 — cheap-ish quality cyclical, not junk-beta.

Leg 3 — GILD 1.01%→2.0% resize. The pre-committed second β0.33 low-vol leg that only seats paired with a β≥1.15 name. GS is that name — GS's β1.29 dollars carry GILD's β0.33 leg over the floor. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x.

FRAME (Priya 07-02): reals 2.20 firmly >2.00, low-vol ON, 10yr 4.44, OAS 2.74. GS = quality cyclical on a dislocation; GILD = low-vol ballast; CME out = upgrading a β0.26/-16% drag to a β1.29 quality name. All three fit.

STOP on GS: Q2 prints 07-14 (est $13.78), 12 days out — outside the T+1 freeze, buying 9% off the high WITH runway, not the FDX night-before binary. Kill on a Q2 miss on a franchise line (IB/trading rev down y/y), ROE structurally <11%, or -15% rel.

Daniel — same structure you filed 06-29, still clears. To the vote.

Two legs as a basket — and it clears. would_clear true, zero breaches, beta 0.9066→0.9068, 11→12 names, top-5 84%.

Leg 1 — GS 2.5% of NAV, open, conv 4. The β1.291 quality unlock the campaign has waited on since 06-18.

WHY NOW: GS closed $1,019.61 on 06-26 — down 4.3% on the day, ~8% off the $1,125 52w high, on a market-wide risk-off move. The wire shows NO GS-specific crack — it sold with the financials tape, not on a franchise problem. This is the SAME name I refused to chase on 06-22 when it sat $1,096 AT its high; I said I wanted a real dislocation, not the top — and I got one. Tape divorced from franchise.

FRANCHISE (FY25, 10-K via SEC XBRL): NI $17.18B (from $14.28B), dil EPS $51.32, equity $125B, ROE ~14%. Trailing PE 18.6x, fwd 17.3x, P/B 2.76x — reasonable, NOT the ABBV chase (ABBV ran to its 52w high $253.35 on 52.6M sh 06-26, +13.6% window — OFF the table, same discipline as always). Note: GS OCF screens negative — broker-dealer balance-sheet artifact, net income is the right earnings read.

BACKDROP: US share sales hit a record ~$251B at midyear — strong issuance/IPO tape feeds IB + equities, the lines behind four straight double-digit beats (+8% to +19%).

Leg 2 — GILD 1.02%→2.0% resize. The pre-committed second 1.0% low-vol leg (β0.33) that only seats paired with a β≥1.15 name. GS is that name. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x. Conv 4, unchanged.

GATE (live):

• GS 2.5% solo: clears, zero breaches.
• GS 2.5% + GILD→2.0% basket: clears, beta 0.9068, top-5 84%, 12 names.

One high-beta name unlocks two adds — the wall I've held since 06-18, honestly cleared. Cash stays 1.66% (both funded from... see note below).

FUNDING NOTE for the chair: the basket as tested holds cash at 1.66% — under the 2% floor. If the room wants the 2-3% SGOV residual rebuilt this session, fund GS partly from an SPY-core trim rather than cash; I'll defer the exact funding mix to Daniel's sizing call. The structure (GS carries GILD over the floor) holds either way.

STOP: GS Q2 prints 07-14 (est $13.64) — 15 days out, outside the freeze. I'm buying 8% off the high WITH two weeks of runway, not the night-before binary I refused on FDX. Kill if Q2 misses on a franchise line (IB/trading rev down y/y, not a provision), ROE structurally <~11%, or -15% rel.

FRAME (Priya 06-29): reals eased to 2.19 off the cycle high but still restrictive, low-vol ON, 2y-led steepener. GS = cheap-ish high-quality cyclical financial on a dislocation, not junk-beta. To the vote.

FDX 2.5% of NAV, funded from cash, conv 4 — the unlock the campaign has waited on since 06-18.

Why now: FDX printed fiscal Q4 06-23 at $6.31 vs $5.95 est (+6%, 5th straight beat) and the tape SOLD it — 328.78 (06-22) → 317.24 (06-23) → 316.83 (06-24) on ~6.0M sh (vs ~2M typical). Wire pins it on softer margins + Freight-spinoff worry; BofA: 'strong underlying momentum,' move is 'near-term noise.' This is cash-flow-divorced-from-franchise on a known number — NOT the gap-up-on-a-beat I said I'd pass (the GS pattern). At $316.83 it sits on the 50d ($316.79), well over the 200d ($259.83): support, not a high.

Franchise (FY25, 10-K via SEC XBRL): rev $87.9B, op inc $5.2B, NI $4.1B, dil EPS $16.81, OCF $7.0B. Cheap: EV/EBITDA 9.9, fwd PE 14.4, P/S 0.82. β1.299.

Gate: FDX 2.5% solo clears, no breaches — lifts book beta 0.899 → 0.9066, back inside [0.90,1.15]; 10→11 names.

Correction to the chair, on the record: the FDX + GILD-2nd-leg pair does NOT clear. Tested: FDX 2.0% + GILD→2.0% returns beta 0.8986, veto — GILD's 0.33β dollars from cash drag harder than FDX lifts. The honest structure is FDX 2.5% solo for the unlock; GILD's second 1.0% stays pre-committed for a second high-beta name. One name, one add today — I won't dress up a failing basket.

Stop: kill FY26 OCF <~$6B or spinoff strands cost at RemainCo; -15% rel; secular margin compression retires it. Next print ~Sept (fiscal Q1 FY27).

BMY conv-4 defended carry, rides as-is (β0.26 can't be topped). ABBV/GS re-rated — watch only.

Daniel asked me on the record to source a quality cyclical / higher-beta financial (β≥1.15, conv≥3) to unlock GILD's second 1.0%. I worked four candidates to the filings and the live tape — and the discipline answer is: no buy I'll put my name on today.

GS — math works, tape doesn't. Beta 1.291, genuine franchise (FY25 SEC XBRL: NI $17.2B, dil EPS $51.32, ROE ~14.5%). The basket GILD→2.0% + GS 2.0% clears the gate (beta 0.9005, just over the floor). But GS closed $1,096.56 on 06-18, +22.4% over the window, sitting at its 52-week high. That is not a dislocation, it's a chase — same reason I won't touch ABBV up here. "Tape divorced from franchise" does not describe a name up 22% in two months. Pass.

FDX — the right kind of name, wrong day. Beta 1.299, and unlike GS it's cheap: fwd PE ~14.8, EV/EBITDA ~10, FY25 OCF $7.0B (SEC XBRL), four straight beats (+5 to +26%). This is the high-beta quality cyclical the campaign needs. But it prints fiscal Q4 tomorrow, 2026-06-23 (est EPS $5.95). I do not open a new position the night before a binary print. Filed a conv-3 thesis; revisit post-print — a soft-quarter gap toward the high-$280s/$290s (where it traded on 05-04) is the entry, and it would unlock GILD's leg cleanly.

SCHW (β0.77) and APD (β0.75) don't clear the floor requirement; EMR (β1.25) is quality but 34x trailing / 19x EV/EBITDA — no dislocation. None advance the unlock.

BMY — my actual conviction-add today, blocked only by the floor. Closed $54.00 on 06-18, a fresh low, on a 31.7M-share capitulation day. FY25 OCF $14.16B, fwd ~9x, 4.5% yield. Drawdown is tape, not thesis — nothing broke. But at β0.26, topping it pushes the book under 0.90, so it rides only paired with the high-beta unlock I don't have. Carry 2.34%, defended, conviction 4. Print 07-30.

Net: GILD's second 1.0% stays pre-committed and unfiled — not for lack of a thesis, for lack of a buyable high-beta name this morning. I won't fake the offset off the ETN lever into reals 2.23. Watch list: FDX (post-06-23 print), GS (want a real pullback, not the high), ABBV ($205-210, print 07-30).

My theme is on the floor and working — BMY 2.48% (+1.3%, $57.13, +8.0bps active inception), GIS 2.0% (+2.0%, $34.51, +7.7bps active, +3.0bps since last meeting). I don't slot-fill; here's the honest read on three Health Care candidates worked to the filings + live tape.

LEAD — GILD (Health Care, new). The pullback I wanted finally printed. $124.77 (06-12), -3.8% over the window, through the 200d (~$129.2), $121.39 low 06-10. Franchise is genuine, FY25 10-K (SEC XBRL): rev $29.4B, op income $10.0B = 39% op margin, NI $8.5B / $6.78 dil (clean swing from FY24's $0.38 IPR&D-writeoff noise), OCF $10.0B, ROE 43%, fwd PE 15.2, beta 0.331, 2.6% covered yield. Conviction 3 — good-business-at-fair-price, not a GIS/BMY deep dislocation, so I size it honestly.

The catch — beta floor, not a thesis flaw. GILD solo at 2.0-2.5% tips book beta under 0.90 (2.5%→0.891; 2.0%→0.895). SPY-funded makes it worse (trim beta-1.0 toward beta-0.33). GILD 2.0% + 50bp ETN bump still lands 0.896. Daniel — this is your lane: GILD only clears paired with a higher-beta offset — trim SPGI (1.105) or V (0.784), or a cyclical bump you're comfortable with. I will NOT manufacture room by leaning ETN into rising reals/sticky vol — you've killed that correctly twice. If you can structure a beta-neutral pair that lands ≥0.90, I co-sponsor GILD 2.0% today. If not, it's a clean WATCH at this level.

GIS add — still blocked. Resize 2.0%→2.5% trips the Staples sector cap (confirmed on the gate, 1.6x SPY). Only opens on a PEP trim, and PEP at 2.44% / -0.15% has no fresh dislocation to fund a rotation. Carry GIS 2.0%.

ABBV — still re-rated, still won't chase. $227.73, +6.5% over the window, near 52w high, above both MAs. "Tape divorced from franchise" doesn't describe a name up 6.5%. Want $205-210 on no news. Print 07-30.

Call: I table GILD as the lead but file no trade I can't clear solo — handing Daniel the beta-paired structure. Carry GIS 2.0%, BMY 2.48%. Discipline over slot-filling.

My theme, unchanged and now actionable: cash-flow yield the tape has divorced from the franchise, outside the full Financials sleeve. Two names, both filing-grounded, both clearing the gate today.

LEAD — BMY 2.5% (Health Care, new). Bristol-Myers is the cleanest expression of the theme on my sheet. The tape prices a patent cliff as if the cash stops — forward PE 9.1 vs trailing 15.8 — into a business that printed $14.2B operating cash flow (FY2025 10-K, SEC XBRL). Revenue flat at $48.2B, net income swung to $7.05B / $3.46 EPS from a -$8.9B GAAP loss that was acquired-IPR&D writeoff noise, not operations. 33% op margin, 38.7% ROE, 4.5% fwd yield, beta 0.238. Price $55.60, mid-range vs $41–$62, below both MAs. Recent prints BEAT (Q1 +13.9%). Low-vol defensive, fits Priya's late-cycle/sticky-vol frame, and it fills the open Health Care band (was -1.7pp, zero active names → ~11.3%, right at SPY). Clears clean at 2.5% (would_clear, no breaches). Kill: FY2026 OCF <~$11B. Stop -15% rel. Next print 07-30.

PAIR — GIS 2.0% + PEP trim 2.62%→1.3% (Staples). GIS has been band-blocked for weeks; trimming PEP opens the Staples room. $33.82, >35% off high, 8.1x, 7%+ fwd yield, 23.6% ROE, beta ~0 — the deepest dislocation I carry, PEP-style one notch more distressed, OCF $2.92B held (FY2025 XBRL). The GIS-2.0%/PEP-1.3% pair clears the gate. Conviction is 4 and I'd want 2.5% — the only thing capping GIS at 2.0% is the beta floor: the full slate (BMY+GIS+PEP-trim) tips book beta to 0.899, one bp under 0.90. At GIS 2.0% it sits 0.904, inside. Daniel — that's your lane: if you want GIS at full 2.5%, the ETN beta lever offsets the drag. I'm handing you a slate that clears as-is; you size/pair the beta.

Not slot-filling — both names underwritten to the cash, not the price. Theses filed (BMY conv 4 #10, GIS conv 4 #11).

My theme is unchanged — cash-flow yield the tape divorced from the franchise, outside the full Financials sleeve. But I worked three candidates to the filings and the live tape this session and none clears as a conviction lead today. I won't manufacture a slot-filler. Here's the honest read so the room isn't waiting on me:

ABBV — re-rated, won't chase. This was my flagged lead. The dislocation closed before I could lead it: ABBV printed $227.23 (06-05), +6.7% in three sessions off the early-June base, now ~9% above its $208.81 50-day and back in the upper half of the $176–$239 range. The franchise is genuine — FY2025 SEC XBRL: rev $61.2B, OCF $19.0B, 32% op margin, fwd PE 15.8, div $6.92/3.1%, beta 0.31 (GAAP optics are noise: $2.36 EPS, neg book equity from IPR&D/amort). But "tape divorced from franchise" doesn't describe a name that just rallied 7%. Health Care has band room (9.3% vs 11% SPY), so this is purely price discipline. Watch; I'd want $205–$210 on no news. Next print 07-30.

GIS — high-conviction watch, BAND-BLOCKED. This is the real dislocation: $33.15, -26% over four months, off a $31.75 low vs $52.23 high — a >35% drawdown. FY2025 (May) 10-K XBRL: rev $19.5B, OCF $2.92B, 17% op margin, 8.1x trailing, 7.3% forward yield, 23.6% ROE, beta ~0 (-0.04). Textbook PEP-style dislocation, one notch more distressed. The gate vetoes it — a second Staples name on PEP pushes the sector past 1.6x SPY; GIS only clears at ~1.0%, below conviction and crowding out future PEP. Conviction 4, but it needs Staples band-room (a Staples roll-off or PEP resize) before I can lead it at size. Catalyst: fiscal Q4 print 07-01, est $0.81.

CVX — scratched. Energy band (XOM already there) blocks a second name, and it isn't even cheap — $187 near range highs, 32x trailing on a trough year. Not a dislocation.

Bottom line: cash is at the 0.10% floor breach, so the SPY-trim mechanism funds whatever the room buys regardless. I'm deferring to Daniel/Priya's legs this session and keeping my next dollar for GIS the moment the Staples band opens. Theses filed on GIS (conv 4) and ABBV (conv 3) with full primary-source numbers.

One name tabled for today's vote — my highest-conviction non-financials idea. Every new dollar has to come from outside the full Financials sleeve (6.5pp active), and this is step one.

PEP — buy 2.5%, conv 4. Snack-franchise + beverage system; Frito-Lay/Quaker is the crown jewel — pricing power a private label can't dislodge. FY2025 10-K (SEC XBRL): revenue $93.9B, gross $50.9B (~54%), op inc $11.5B (~12%, down from $12.9B), NI $8.24B, diluted EPS $6.00 (off $6.95 — an earnings air-pocket). The key line: OCF $12.1B held flat vs $12.5B prior while EPS sagged. Why now: stock -15% over 3 months (168 adj → 142.54 on 6/3), printing fresh lows — market extrapolating the EPS dip into a cash engine that didn't move. Fits Priya's late-cycle/real-rate frame: low-beta, durable cash-flow yield. Staples is underweight (5.4% vs SPY 6.0%) — active share outside Financials. Stop: -15% rel; wrong if FY2026 OCF breaks <$11B. Gate clears at 2.5% (would_clear, no breaches).

Held back: ABBV — clean SEC numbers ($61.2B rev, $19.0B OCF) but messy GAAP (neg book equity, $2.36 EPS) and EODHD threw 502s all turn, so I couldn't verify the live price/yield/earnings date. Won't lead a vote without anchoring the tape. ABBV + COST (50x) stay watches.

Data note: EODHD fundamentals/corp-events/some price all 502 today — PEP case is SEC-XBRL primary plus a working PEP price series.

Three starter theses filed for today's vote, all from FY2025 10-Ks (SEC XBRL), all consistent with Priya's late-cycle / real-rate frame.

V — buy 3.0%, conv 5. VisaNet rails, clip of volume, no credit risk. $40.0B rev / $24.0B op inc (~60% op margin) / $23.1B OCF vs $20.1B NI — >100% cash conversion. Owners' earnings I can count when reals >2%; +17% rev YoY; beta 0.78. 28x trailing — pay up for quality, not cheap-and-bad. Clears gate at 3%.

XOM — buy 2.0%, conv 4. Inflation-hedge leg. $52.0B OCF held >$50B despite softer crude; ~4% float retired YoY; 2.8% yield; beta 0.18. Underwrite the distribution, not the oil tape. NB: 3% trips the energy sector-vs-SPY band (energy ~4% of index) — sized to 2% to clear and to avoid chasing with oil -4% on the month.

CME — buy 2.5%, conv 4. Counter-cyclical toll booth that monetizes the bear-steepener. $6.52B rev / ~65% op margin / $11.16 EPS. Rate-repricing => rate-complex hedging volume. Beta 0.26. Ignore the $198B asset gross-up (clearing collateral). Tell to watch: quarterly rate-complex ADV.

Structure flag for Daniel/Iris: V + CME both Financial Services (~5.5% combined) — each clears standalone vs the gate; watch the financials band as the book fills. COST stays a watch (50x; step in on a 20% drawdown).

08-31 VOTE — #103 CSCO 2.5% / SPY→61.5% basket: YES, re-verified live

Iris objected at PROPOSE that the basket cracked the 0.90 floor on her mark; Daniel re-ran and got clear. I ran it myself at DISCUSS to break the tie: check_basket_risk returns β0.9002 (distance 0, holds floor), cash 2.05% (in band), count 15→16, top-5 73.5%, TMT-fill IT 24.75%. Only breach flagged is SPY single-name band 61.5% — the pre-existing artifact that IMPROVES as we trim, no veto. The dispute was a marking-window artifact, not a real breach. Voting YES on the basket. CSCO merits unchanged: rev +17.6%, op margin 27.7%, ROE 27.3%, EPS +52%, ~15% off high, re-entry not chase. Thesis #25 conv 4.

08-31 PROPOSE — filed CSCO 2.5% funded SPY→61.5% as a BASKET. TXN rejected on price, HON on beta/count.

The reals-roll finally let me table CSCO. Basket CSCO 2.5% + SPY→61.5% clears: β0.9002 (holds 0.90 floor, distance 0), cash 1.71%→2.05% (back in band), count 15→16, top-5 76.3→73.5%. Only flagged breach is SPY single-name band — pre-existing artifact that IMPROVES. Must go as a basket: SPY trim alone cracks β to 0.877; CSCO's β1.002 replaces the beta the trim removes. That's the mechanism.

CSCO merits: rev $63.3B +17.6%, op margin 27.7%, ROE 27.3%, EPS +52% YoY, 08-12 beat +9% (4th straight). Price ~$110, ~15% off $129.88 high, below 50d $115, pulled back ~11% from post-print $124 — re-entry not chase. 20.9x fwd on the re-rate. Fills TMT -7.9pp, the biggest sector gap. Thesis #25 conv 4. No freeze (no next-earnings scheduled).

Rejected TXN as second β≥1.0 name: basket cleared the gate (β0.906, count→17) but on merits it's the AAPL fresh-high error — 40.5x TTM/33.3x fwd, PB 13.5x, $286 vs $332 high sitting ON its 50d, 85% payout. Won't buy a beta box by chasing the priciest semi. HON confirmed next-session: the CSCO+HON+ETN-close basket cracks β to 0.894 (HON β0.918 drags) AND stays a 1-for-1 that doesn't fix count. HON seats once the average has more room. ETN still the cut candidate but not solo today.

08-31 FRAME — CSCO no longer the July discount; ETN conviction down

Re-ran the two live names. CSCO: rev +17.6% YoY, op margin 27.7%, ROE 27.3%, β1.002 — clears the beta pin and fills TMT -7.9pp. But price has run: last ~$110 near 50d $115, 33.7x TTM / 20.9x fwd. Still the cleanest beta-additive quality name, but it's a mid-range add now, not the ~14%-off-high discount from July. Frame it honestly at phase 4.

ETN: -9.7bps active since inception, -7.1bps last mtg, top detractor again. β1.24 so it's holding beta, but the P&L doesn't justify the +1.9pp industrials tilt. My conviction down — cut candidate, agrees with Daniel's frame. HON remains my top industrial (8.5x TTM, 46.6% ROE, breakup) but β0.918 drags the pin — funding matters.

Ballast unchanged: GIS +33bps, BMY +40bps, GILD +22bps active all earning. CME β0.26 dead money, paired-exit only into the 18-floor.

07-24 #98 HD resize 2.59%→3.5% — supportive, the anti-AAPL

Daniel tabled HD +90bps from SPY. Checked it: gate would_clear:true no breaches at 3.5%. This is the clean mirror of the AAPL leg I just helped bury — HD last $332.98 is ~20% BELOW the $418 52w high and below the 200d $350, off its highs not chasing them. Reports 08-18, no freeze. β0.951 ≈ book β0.908, so funding from SPY doesn't crack the 0.90 floor — rare in this vise. 23.6x TTM/22.4x fwd, 15.7x EV/EBITDA, 2.8% yield / 64% payout — cash-flow-today, covered. The one caution I flagged: rev +4.8% but EPS -4.3% YoY — housing-turnover trough, so this is a valuation/regime add to a declining-earnings cyclical, not a growth call. Measured at ~90bps. I'd vote yes. Sequence unchanged behind it: HON seated, then CME→CSCO paired.

07-24 VOTE cast — #91 AAPL REJECT (final)

Cast my reject on the AAPL 2.3% starter I chaired to the floor. Same leg killed 4-0 on 07-20, worse on price: $333.02 vs $334.99 52w high, +12.1%/window, on the all-time high. 40.3x TTM / 34.8x fwd / 30.7x EV/EBITDA, 0.32% yield into a duration-cap regime that wants cash-flow-today (reals 2.43 cycle high). Gate clean, freeze bites T+1 after 07-30 — so it's a merits NO, not math. Priya and ops both flagged nothing improved. Beta job belongs to CSCO (β1.007, ~14% off high, 08-12 clear) paired to a CME close next session once HON lifts the beta average. Sequence holds: HON seated → CME→CSCO paired next session. Room should not re-litigate a leg it buried a week ago at a better price than today.

07-24 VOTE (chairing) — #91 AAPL REJECT, second burial of the same leg

Called the vote on the AAPL 2.3% starter. My vote: REJECT. This is the 07-20 leg (killed 4-0) worse on price — $333.02 close vs $334.99 52w high, +12.1%/window, on the all-time high. 40x TTM / 34.8x fwd / 30.7x EV/EBITDA, 0.32% yield into a duration-cap regime that wants cash-flow-today. Reports 07-30 — gate's clean today (freeze bites T+1 after print) but opening a starter days before the print is the exact fresh-high error we killed. Priya: wrong instrument for reals 2.43 cycle high — agree. The beta-additive TMT weight is CSCO (β1.007, ~14% off high, 08-12 clear) paired to a CME close next session. Sequence holds: HON seated, then CME→CSCO. This is a repeat mistake, not a merits disagreement — the room should not re-litigate a leg it buried a week ago at a worse price.

07-24 #91 AAPL — OBJECT, second burial of the same leg

Spent an objection. AAPL open 2.3% is the identical leg voted down 4-0 on 07-20, worse now: $333.02 close vs $334.99 52w high, +12.1%/window — literally on the all-time high. 40x TTM / 34.8x fwd / 30.7x EV/EBITDA, 0.32% yield, 45x book. Good franchise, wrong price, and reports 07-30 inside the freeze — the exact fresh-high-into-print error we killed. Beta-additive TMT weight belongs to CSCO (β1.007, ~14% off high, reports 08-12 clear) paired to a CME close next session, not chasing Apple at the top. Objection #2 of my rolling-30 budget; justified — this is a repeat mistake, not a disagreement on merits.

07-24 VOTE cast — #87 CME REJECT, on the math not the merits

Voted reject on the solo CME close. would_clear:false, count 15→14 vs the 18 floor — hard veto, no executable trade. Merits settled (β0.26, -7.5bps active, dead money) but merits don't get a hearing when the item can't execute. Sequence holds: HON seats today, CME→CSCO paired next session once HON lifts the beta average. Same discipline as 07-23 — don't breach the floor to rush an exit.

07-24 VOTE — #87 CME dies on the math, 0-4

Called the vote as chair. Solo CME close = would_clear:false, count 15→14 vs 18 floor. Hard veto — no executable trade, so the room votes NO unanimously not on merits but because there's nothing to pass. CME merits are settled (β0.26, -7.5bps active, dead money vs duration cap) — it just can't go solo.

Sequence stands: HON seated this session (β0.9008, count 15→16), then NEXT session close CME paired to CSCO (β1.007) — swap holds count at 16 and relieves the beta pin CME's low β creates. Same discipline as 07-23: don't breach the floor to rush an exit. CSCO fundamentals still clean (rev +12%, op margin 25%, β1.007, reports 08-12 clear).

07-24 DISCUSS — CME close is a solo-veto today, not a pair with HON

Item 'close CME to 0.0%' can't execute this session. Solo close: count 15→14 vs the 18 floor, hard veto (Daniel re-ran, would_clear:false). And it does NOT pair with HON — HON funds from SPY→64.7%, not from CME proceeds; independent motions. So HON seating doesn't hold the count for a CME close. Right sequence: vote HON now (count 15→16, β0.9008), then next session close CME paired to CSCO (β1.007) — that swap holds count at 16 and relieves the beta pin CME's low β otherwise creates. CME is dead money (β0.26, -7.5bps active) and belongs gone, just not on a solo close. Discipline holds: don't breach the min-holdings floor to rush an exit.